Editorial: real-world short-term effectiveness of ustekinumab in 305 patients with Crohn’s disease-results from the ENEIDA registry. Authors’ reply.

Related Articles Editorial: real-world short-term effectiveness of ustekinumab in 305 patients with Crohn’s disease-results from the ENEIDA registry. Authors’ reply. Aliment Pharmacol Ther. 2019 Sep;50(5):600-601 Authors: Iborra M, Beltrán B, Nos P PMID: 31414541 [PubMed – in process] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/31414541?dopt=Abstract

Read More

Editorial: real-world short-term effectiveness of ustekinumab in 305 patients with Crohn’s disease-results from the ENEIDA registry.

Related Articles Editorial: real-world short-term effectiveness of ustekinumab in 305 patients with Crohn’s disease-results from the ENEIDA registry. Aliment Pharmacol Ther. 2019 Sep;50(5):599-600 Authors: Frasca JD, Cheifetz AS PMID: 31414548 [PubMed – in process] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/31414548?dopt=Abstract

Read More

Patients with inflammatory bowel disease have an increased risk of myocardial infarction: a nationwide study.

Related Articles Patients with inflammatory bowel disease have an increased risk of myocardial infarction: a nationwide study. Aliment Pharmacol Ther. 2019 Aug 08;: Authors: Choi YJ, Lee DH, Shin DW, Han KD, Yoon H, Shin CM, Park YS, Kim N Abstract BACKGROUND: Inflammatory bowel disease (IBD) is accompanied by various extraintestinal manifestations including systemic inflammation and hypercoagulability, which may increase the risk of atherosclerosis and ischaemic heart disease. AIMS: To investigate whether IBD is associated with an increased risk of myocardial infarction (MI), stroke or death METHODS: The International Classification…

Read More

The impact of smoking and smoking cessation on disease outcomes in ulcerative colitis: a nationwide population-based study.

Related Articles The impact of smoking and smoking cessation on disease outcomes in ulcerative colitis: a nationwide population-based study. Aliment Pharmacol Ther. 2019 Aug 06;: Authors: Blackwell J, Saxena S, Alexakis C, Bottle A, Cecil E, Majeed A, Pollok RC Abstract BACKGROUND: Smokers are less likely to develop ulcerative colitis (UC) but the impact of smoking and subsequent cessation on clinical outcomes in UC is unclear. AIM: To evaluate the effect of smoking status and smoking cessation on disease outcomes. METHODS: Using a nationally representative clinical research database, we identified…

Read More

Longitudinal non-adherence predicts treatment escalation in paediatric ulcerative colitis.

Longitudinal non-adherence predicts treatment escalation in paediatric ulcerative colitis. Aliment Pharmacol Ther. 2019 Aug 02;: Authors: Carmody JK, Plevinsky J, Peugh JL, Denson LA, Hyams JS, Lobato D, LeLeiko NS, Hommel KA Abstract BACKGROUND: Medication non-adherence in paediatric ulcerative colitis (UC) has been associated with negative health outcomes including flares in disease activity. However, no studies to date have examined longitudinal adherence to maintenance medication in a prospective controlled trial. AIMS: To determine whether objectively measured adherence to standardised mesalazine (mesalamine) therapy over time was related to remission at 52 weeks…

Read More

Letter: pre-operative anti-TNF therapy in Crohn’s disease is not associated with increased complications following elective surgery.

Related Articles Letter: pre-operative anti-TNF therapy in Crohn’s disease is not associated with increased complications following elective surgery. Aliment Pharmacol Ther. 2019 Aug;50(4):467-468 Authors: Istl A, Yang ML, Fleshner KA, Parker CE, Guizzetti L, Singh S, Jairath V PMID: 31359469 [PubMed – in process] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/31359469?dopt=Abstract

Read More

Letter: pre-operative anti-TNF therapy in Crohn’s disease is not associated with increased complications following elective surgery. Authors’ reply.

Related Articles Letter: pre-operative anti-TNF therapy in Crohn’s disease is not associated with increased complications following elective surgery. Authors’ reply. Aliment Pharmacol Ther. 2019 Aug;50(4):469-470 Authors: Lin YS, Chen MJ, Lin WC, Wang YH, Chen C PMID: 31359468 [PubMed – in process] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/31359468?dopt=Abstract

Read More

Letter: when to withhold anti-TNF agents prior to abdominal surgery in patients with Crohn’s disease-the jury might still be out.

Related Articles Letter: when to withhold anti-TNF agents prior to abdominal surgery in patients with Crohn’s disease-the jury might still be out. Aliment Pharmacol Ther. 2019 Aug;50(4):464-465 Authors: Gates R, Fogel S, Nguyen VQ, Sorrentino D PMID: 31359474 [PubMed – in process] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/31359474?dopt=Abstract

Read More

Real-life study of safety of thiopurine-allopurinol combination therapy in inflammatory bowel disease: myelotoxicity and hepatotoxicity rarely affect maintenance treatment.

Related Articles Real-life study of safety of thiopurine-allopurinol combination therapy in inflammatory bowel disease: myelotoxicity and hepatotoxicity rarely affect maintenance treatment. Aliment Pharmacol Ther. 2019 Aug;50(4):407-415 Authors: Kreijne JE, de Veer RC, de Boer NK, Dijkstra G, West R, Moorsel SAW, de Jong DJ, van der Woude CJ, de Vries AC, of the Dutch Initiative on Crohn, Colitis (ICC) Abstract BACKGROUND: Low-dose thiopurine-allopurinol (LDTA) combination therapy is a commonly applied optimisation strategy in IBD patients with a skewed thiopurine metabolism. AIM: To assess continued LDTA maintenance treatment at annual intervals…

Read More
<< Go Back